Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$362K Hold
1,000
0.1% 42
2026
Q1
$349K Sell
1,000
-41
-4% -$14.6K 0.11% 41
2025
Q4
$341K Hold
1,041
0.13% 36
2025
Q3
$294K Buy
1,041
+582
+127% +$169K 0.1% 42
2025
Q2
$291K Sell
459
-582
-56% -$165K 0.11% 44
2025
Q1
$324K Hold
1,041
0.13% 36
2024
Q4
$271K Hold
1,041
0.14% 41
2024
Q3
$335K Hold
1,041
0.17% 39
2024
Q2
$325K Hold
1,041
0.14% 40
2024
Q1
$296K Sell
1,041
-37
-3% -$10.8K 0.13% 45
2023
Q4
$310K Hold
1,078
0.15% 40
2023
Q3
$290K Buy
+1,078
New +$269K 0.16% 38
2023
Q2
Sell
-1,184
Closed -$286K 53
2023
Q1
$286K Buy
1,184
+6
+0.5% +$1.47K 0.15% 41
2022
Q4
$309K Buy
+1,178
New +$316K 0.18% 39

Other funds holding AMGN

Waterford Advisors's AMGN Position: Q2 2026 in Review

Waterford Advisors held its Amgen (AMGN) position steady in Q2 2026 at 1,000 shares worth $362K. The position accounts for 0.1% of the portfolio, ranked #42.

Waterford Advisors first reported a position in AMGN in Q4 2022 and has held it in 14 quarters since. 3,133 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Waterford Advisors held 1,000 shares of Amgen worth $362K as of Q2 2026.
  • Waterford Advisors left its Amgen share count unchanged in Q2 2026.
  • Amgen made up 0.1% of Waterford Advisors's portfolio in Q2 2026, its #42 holding.
  • Waterford Advisors first reported a position in Amgen in Q4 2022 and has held it in 14 quarters since.
  • 3,133 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Waterford Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.